首页 | 本学科首页   官方微博 | 高级检索  
     


Discovery of an Anion-Dependent Farnesyltransferase Inhibitor from a Phenotypic Screen
Authors:Marina Bukhtiyarova  Erica M. Cook  Paula J. Hancock  Alan W. Hruza  Anthony W. Shaw  Gregory C. Adam  Richard J. O. Barnard  Philip M. McKenna  M. Katharine Holloway  Ian M. Bell  Steve Carroll  Ivan Cornella-Taracido  Christopher D. Cox  Peter S. Kutchukian  David A. Powell  Corey Strickland  B. Wesley Trotter  Matthew Tudor  Scott Wolkenberg  Jing Li  David M. Tellers
Affiliation:MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States;MRL, Merck & Co., Inc., Boston, Massachusetts, 02115, United States;§MRL, Merck & Co., Inc., Kenilworth, New Jersey, 07033, United States
Abstract:By employing a phenotypic screen, a set of compounds, exemplified by 1, were identified which potentiate the ability of histone deacetylase inhibitor vorinostat to reverse HIV latency. Proteome enrichment followed by quantitative mass spectrometric analysis employing a modified analogue of 1 as affinity bait identified farnesyl transferase (FTase) as the primary interacting protein in cell lysates. This ligand-FTase binding interaction was confirmed via X-ray crystallography and temperature dependent fluorescence studies, despite 1 lacking structural and binding similarity to known FTase inhibitors. Although multiple lines of evidence established the binding interaction, these ligands exhibited minimal inhibitory activity in a cell-free biochemical FTase inhibition assay. Subsequent modification of the biochemical assay by increasing anion concentration demonstrated FTase inhibitory activity in this novel class. We propose 1 binds together with the anion in the active site to inhibit farnesyl transferase. Implications for phenotypic screening deconvolution and HIV reactivation are discussed.
Keywords:HIV latency   phenotypicscreen   HDAC inhibitor   farnesyltransferase inhibitor
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号